Thymosin Alpha-1 vs Thymulin
A side-by-side research comparison of Thymosin Alpha-1 and Thymulin across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Thymosin Alpha-1 | Thymulin |
|---|---|---|
| Full name | Thymosin Alpha-1 (Thymalfasin) | Thymulin (Facteur Thymique Serique) |
| Category | Immune Support | Immune Support |
| Status | Approved internationally (not FDA-approved) | Research compound |
| Mechanism | Activates toll-like receptors (TLR2, TLR9) on dendritic cells, promotes T-cell maturation and differentiation, enhances NK cell cytotoxicity, and modulates cytokine profiles. | Binds to specific receptors on T-cell precursors promoting their differentiation into mature T-cells, modulates cytokine production, and requires zinc as cofactor. |
| Molecular weight | 3108.3 Da | 847.9 Da |
| Half-life | ~2-3 hours | ~2 hours |
| Bioavailability | ~85% subcutaneous | ~80% subcutaneous |
| Typical dose | 1.6-3.2 mg | 1-5 mg |
| Frequency | 2-3x per week | 2-3x per week |
| Route | Subcutaneous injection | Subcutaneous injection |
Thymosin Alpha-1 reported benefits
- Enhanced T-cell immunity
- Anti-viral activity
- Dendritic cell activation
- Cancer immunosurveillance
- Vaccine adjuvant effects
Thymulin reported benefits
- T-cell maturation support
- Thymic function restoration
- Zinc-dependent immune activation
- Anti-inflammatory properties
Related comparisons
Research and educational reference only. Not medical advice.